Rozanolixizumab & Biosimilar Ustekinumab Among Raft Of New Drugs Filed In EU

 
• By Neena Brizmohun

The European Medicines Agency’s latest list of drugs under review for potential marketing approval includes a second generalized myasthenia gravis treatment from UCB and what could become the first biosimilar version of Stelara in the EU.

CDE drug review
A new batch of drug filings are now under review in the EU • Source: Shutterstock

More from Europe

More from Geography